Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

Science Translational Medicine

Volumn 6, Issue 238, 2014, Pages

  Cha, Edward ^a   Klinger, Mark ^b   Hou, Yafei ^a   Cummings, Craig ^b   Ribas, Antoni ^c   Faham, Malek ^b   Fong, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sequenta Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TICILIMUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL EXPANSION; CELL LOSS; CELL METABOLISM; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE REARRANGEMENT; GENE SEQUENCE; GENE TECHNOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; METASTATIC MELANOMA; NEXT GENERATION DEEP SEQUENCING; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR GENE; SURVIVAL TIME; T CELL CLONOTYPE; T LYMPHOCYTE; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASMS; SURVIVAL;

ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84902825664     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008211     Document Type: Article

References (50)

1. S. S. Kwek, E. Cha, L. Fong, Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat. Rev. Cancer 12, 289-297 (2012).
2. M. F. Krummel, J. P. Allison, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533-2540 (1996).
3. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
4. S. A. Quezada, K. S. Peggs, M. A. Curran, J. P. Allison, CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935-1945 (2006).
5. D. R. Leach, M. F. Krummel, J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
6. M. J. Selby, J. J. Engelhardt, M. Quigley, K. A. Henning, T. Chen, M. Srinivasan, A. J. Korman, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32-42 (2013).
7. Y. Bulliard, R. Jolicoeur, M. Windman, S. M. Rue, S. Ettenberg, D. A. Knee, N. S. Wilson, G. Dranoff, J. L. Brogdon, Activating Fc g receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693 (2013).
8. T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, J. V. Ravetch, J. P. Allison, S. A. Quezada, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
9. J. D. Wolchok, F. S. Hodi, J. S. Weber, J. P. Allison, W. J. Urba, C. Robert, S. J. O'Day, A. Hoos, R. Humphrey, D. M. Berman, N. Lonberg, A. J. Korman, Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. N. Y. Acad. Sci. 1291, 1-13 (2013).
10. A. Ribas, D. C. Hanson, D. A. Noe, R. Millham, D. J. Guyot, S. H. Bernstein, P. C. Canniff, A. Sharma, J. Gomez-Navarro, Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12, 873-883 (2007).
11. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. M. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
12. E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, J. P. Allison, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13, 1810-1815 (2007).
13. S. F. Slovin, C. S. Higano, O. Hamid, S. Tejwani, A. Harzstark, J. J. Alumkal, H. I. Scher, K. Chin, P. Gagnier, M. B. McHenry, T. M. Beer, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann. Oncol. 24, 1813-1821 (2013).
14. L. Fong, S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, E. J. Small, Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69, 609-615 (2009).
15. B. I. Rini, L. Fong, V. Weinberg, B. Kavanaugh, E. J. Small, Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J. Urol. 175, 2087-2091 (2006).
16. + T cells in a dose-dependent fashion. Blood 112, 1175-1183 (2008).
17. G. Y. Ku, J. Yuan, D. B. Page, S. E. A. Schroeder, K. S. Panageas, R. D. Carvajal, P. B. Chapman, G. K. Schwartz, J. P. Allison, J. D. Wolchok, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767-1775 (2010).
18. W. Wang, D. Yu, A. A. Sarnaik, B. Yu, M. Hall, D. Morelli, Y. Zhang, X. Zhao, J. S. Weber, Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J. Transl. Med. 10, 146 (2012).
19. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U.S.A. 108, 16723-16728 (2011).
20. O. Hamid, H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal, J. Hansson, M. Guida, D. M. Hyams, H. Gómez, L. Bastholt, S. D. Chasalow, D. Berman, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
21. R. R. Ji, S. D. Chasalow, L. Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N. O. Siemers, J. R. Jackson, V. Shahabi, An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
22. + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol. Immunother. 62, 245-256 (2013).
23. J. G. Egen, J. P. Allison, Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16, 23-35 (2002).
24. J. G. Egen, M. S. Kuhns, J. P. Allison, CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
25. M. Klinger, K. Kong, M. Moorhead, L. Weng, J. Zheng, M. Faham, Combining next-generation sequencing and immune assays: A novel method for identification of antigen-specific T cells. PLOS One 8, e74231 (2013).
26. H. Robins, Immunosequencing: Applications of immune repertoire deep sequencing. Curr. Opin. Immunol. 25, 646-652 (2013).
27. + T cell receptor repertoire. Sci. Transl. Med. 2, 47ra64 (2010).
28. E. von Euw, T. Chodon, N. Attar, J. Jalil, R. C. Koya, B. Comin-Anduix, A. Ribas, CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).
29. M. Morisita, Measuring of interspecific association and similarity between communities. Mem. Fac. Sci. Kyushu Univ. Ser. E (Biol.) 3, 65-80 (1959).
30. S. Anders, W. Huber, Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
31. J. D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, W. Waterfield, D. Schadendorf, M. Smylie, T. Guthrie Jr., J. J. Grob, J. Chesney, K. Chin, K. Chen, A. Hoos, S. J. O'Day, C. Lebbé, Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
32. P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, M. C. Christian, S. G. Gwyther, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
33. H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W. K. Kelly, W. D. Figg, E. J. Small, T. M. Beer, G. Wilding, A. Martin, M. Hussain; Prostate Cancer Clinical Trials Working Group, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
34. + T-cell activation is associated with acute rejection in lung transplantation. Clin. Immunol. 148, 16-26 (2013).
35. F. Yang, X. Li, M. Sharma, M. Zarnegar, B. Lim, Z. Sun, Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. J. Biol. Chem. 276, 15345-15353 (2001).
36. S. S. Kwek, V. Dao, R. Roy, Y. Hou, D. Alajajian, J. P. Simko, E. J. Small, L. Fong, Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J. Immunol. 189, 3759-3766 (2012).
37. B. Comin-Anduix, Y. Lee, J. Jalil, A. Algazi, P. de la Rocha, L. H. Camacho, V. A. Bozon, C. A. Bulanhagui, E. Seja, A. Villanueva, B. R. Straatsma, A. Gualberto, J. S. Economou, J. A. Glaspy, J. Gomez-Navarro, A. Ribas, Detailed analysis of immunologic effects of the cytotoxic T lymphocyte- associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 6, 22 (2008).
38. I. Messaoudi, J. A. Guevara Patiño, R. Dyall, J. LeMaoult, J. Nikolich-Zugich, Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298, 1797-1800 (2002).
39. D. A. Price, S. M. West, M. R. Betts, L. E. Ruff, J. M. Brenchley, D. R. Ambrozak, Y. Edghill-Smith, M. J. Kuroda, D. Bogdan, K. Kunstman, N. L. Letvin, G. Franchini, S. M. Wolinsky, R. A. Koup, D. C. Douek, T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21, 793-803 (2004).
40. L. Trautmann, M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville, Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175, 6123-6132 (2005).
41. + T cells. Immunity 38, 425-436 (2013).
42. + T cells can dominate in the peripheral circulation for at least 18 years. Blood 106, 4412-4413 (2005).
43. D. E. Speiser, P. Baumgaertner, C. Barbey, V. Rubio-Godoy, A. Moulin, P. Corthesy, E. Devevre, P. Y. Dietrich, D. Rimoldi, D. Liénard, J. C. Cerottini, P. Romero, N. Rufer, A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: Spontaneous priming and efficient boosting by vaccination. J. Immunol. 177, 1338-1348 (2006).
44. + T cell clonotypes is not limited by replicative senescence or functional alteration. J. Immunol. 179, 2368-2379 (2007).
45. N. van Rooij, M. M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L. J. A. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, M. Nieuwland, M. R. Stratton, R. M. Kerkhoven, C. Kesmir, J. B. Haanen, P. Kvistborg, T. N. Schumacher, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
46. P. F. Robbins, Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, Y. Samuels, S. A. Rosenberg, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
47. + T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: Human cytomegalovirus. J. Immunol. 179, 3203-3213 (2007).
48. M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis, A. Sivachenko, S. L. Carter, C. Stewart, C. H. Mermel, S. A. Roberts, A. Kiezun, P. S. Hammerman, A. McKenna, Y. Drier, L. Zou, A. H. Ramos, T. J. Pugh, N. Stransky, E. Helman, J. Kim, C. Sougnez, L. Ambrogio, E. Nickerson, E. Shefler, M. L. Cortés, D. Auclair, G. Saksena, D. Voet, M. Noble, D. DiCara, P. Lin, L. Lichtenstein, D. I. Heiman, T. Fennell, M. Imielinski, B. Hernandez, E. Hodis, S. Baca, A. M. Dulak, J. Lohr, D. A. Landau, C. J. Wu, J. Melendez-Zajgla, A. Hidalgo-Miranda, A. Koren, S. A. McCarroll, J. Mora, R. S. Lee, B. Crompton, R. Onofrio, M. Parkin, W. Winckler, K. Ardlie, S. B. Gabriel, C. W. M. Roberts, J. A. Biegel, K. Stegmaier, A. J. Bass, L. A. Garraway, M. Meyerson, T. R. Golub, D. A. Gordenin, S. Sunyaev, E. S. Lander, G. Getz, Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
49. B. Comin-Anduix, H. Sazegar, T. Chodon, D. Matsunaga, J. Jalil, E. von Euw, H. Escuin-Ordinas, R. Balderas, B. Chmielowski, J. Gomez-Navarro, R. C. Koya, A. Ribas, Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLOS One 5, e12711 (2010).
50. H. Wolda, Similarity indices, sample size and diversity. Oecologia 50, 296-302 (1981).